Stock research
NWBO Northwest Biotherapeutics, Inc.
Healthcare • Biotechnology
Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline...…
Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform. This platform harnesses a patient's own activated dendritic cells to stimulate their immune system to combat cancerous cells. The company's leading therapeutic candidate, DCVax-L, has successfully completed Phase III clinical trials targeting Glioblastoma multiforme, an aggressive form of brain cancer. Additionally, Northwest Biotherapeutics is progressing DCVax-Direct through Phase I/II clinical studies, focusing on the treatment of inoperable solid tumors. Founded in 1996, the company's headquarters are situated in Bethesda, Maryland.
3M change
-23.61%
Range high
$0.26
Congress · 90d
0
Insiders · 90d
0
Public signal layer
Who is disclosing activity in NWBO?
Price
Showing 3M history. Source: FMP historical price full.
- Prev Close
- $0.17
- Day High
- $0.17
- Day Low
- $0.16
- 52w High
- $0.37
- 52w Low
- $0.14
- Volume
- 596,508
- Avg Volume
- Beta
- -0.626
* TTM/most recent where available
Company
- Ticker
- NWBO
- Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- CEO
- Linda F. Powers
- Employees
- 105
- Website
- www.nwbio.com
Key Metrics
- Market Cap
- 263M
- P/E
- P/B
- P/S
- EV/EBITDA
- ROE
- Net Margin
- Div Yield
- FCF/Share
* TTM/most recent where available
DCF Valuation
Standard DCF
Levered DCF
Market Price
DCF vs Price (30D window)
Price uses last 30 days; DCF line holds latest value across the window.DCF line = solid green (latest value repeated across window), Price = dashed blue (daily closes).